Calliditas Therapeutics (CALT) has released an update.
Calliditas Therapeutics reported a significant increase in net sales to SEK 559.8 million in Q2 2024, mainly from TARPEYO® sales, with an adjusted operating profit of SEK 70.2 million after excluding one-off expenses. The company also highlighted key milestones, including positive trial data and product launches, and received a public cash offer from Asahi Kasei Corporation at a substantial premium. Looking ahead, Calliditas anticipates continued revenue growth with estimated total net sales from the Nefecon franchise to be USD 165-185 million for the year.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.
